Bimatoprost Sustained Release Implant — Competitive Intelligence Brief

Bimatoprost Sustained Release Implant (Bimatoprost Sustained Release Implant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog. Area: Ophthalmology.

phase 2 Prostaglandin analog FP receptor Ophthalmology Small molecule

Target snapshot

Bimatoprost Sustained Release Implant (Bimatoprost Sustained Release Implant) — AbbVie. Bimatoprost Sustained Release Implant works by releasing bimatoprost, a prostaglandin analog, to lower intraocular pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bimatoprost Sustained Release Implant TARGET	Bimatoprost Sustained Release Implant	AbbVie	phase 2	Prostaglandin analog	FP receptor
IOPIZE© Latanoprost eyedrops	IOPIZE© Latanoprost eyedrops	University of Catanzaro	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Preserved Bimatoprost 0.01%	Preserved Bimatoprost 0.01%	Universitaire Ziekenhuizen KU Leuven	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Latanoprost/Timolol	Latanoprost/Timolol	Universiti Kebangsaan Malaysia Medical Centre	marketed	Prostaglandin analog / Beta-blocker combination	Prostaglandin F receptor (FP receptor) / Beta-adrenergic receptors (β1, β2)
latanoprost 0.005% (drug)	latanoprost 0.005% (drug)	University Hospital, Basel, Switzerland	marketed	Prostaglandin F receptor agonist	FP receptor (prostaglandin F receptor)
Drug: latanoprost/timolol	Drug: latanoprost/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analog/beta-blocker combination	Prostaglandin F receptor (FP receptor) and beta-adrenergic receptors (β1 and β2)
Bimatoprost Ophthalmic Solution	Bimatoprost Ophthalmic Solution	Allergan	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog class)

1. Allergan · 3 drugs in this class
2. AbbVie · 2 drugs in this class
3. Bnai Zion Medical Center · 1 drug in this class
4. Ibis Reproductive Health · 1 drug in this class
5. Ocuwize LTD · 1 drug in this class
6. Shaare Zedek Medical Center · 1 drug in this class
7. University Medical Centre Maribor · 1 drug in this class
8. University of North Carolina, Chapel Hill · 1 drug in this class
9. University of Pennsylvania · 1 drug in this class
10. Wolfson Medical Center · 1 drug in this class